After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
Daylight Saving Time Begins March 10, 2019. As a friendly reminder, airlines often change their rout...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...